Senescent Cells, Osteoporosis, and Alzheimer’s Are Linked

Researchers publishing in Nature Aging have discovered a significant relationship between senescent cells, osteoporosis, and Alzheimer’s disease. Their findings illustrate that bone loss often occurs before Alzheimer's is diagnosed, suggesting a link between amyloid accumulation in bones and senescent cells that produce a specific factor known as SASP (Senescence-Associated Secretory Phenotype).

Key Discoveries

• Bone loss is frequently evident in individuals prior to an Alzheimer's diagnosis.
• Studies reveal substantial bone loss in Alzheimer’s model mice, accompanied by amyloid deposits.
• SASP factors released by senescent cells may promote amyloid aggregation, thus exacerbating bone density issues.
• Interruption of this process shows potential to alleviate amyloid-related osteoporosis in pre-clinical studies.

Understanding the Broader Implications

The amyloid tangles associated with Alzheimer's and other neurodegenerative diseases typically affect the brain. However, amyloid deposits can manifest in various organs, including the liver, kidneys, and heart, leading to a condition known as systemic amyloidosis, which can be life-threatening (source). This occurrence of amyloidosis is frequently linked to aging rather than solely rare genetic disorders (source).

Research shows that individuals diagnosed with Alzheimer’s typically experience bone loss significantly sooner than those without the condition (source). Alzheimer’s model mice exhibit accelerated rates of bone loss compared to wild-type mice (source).

Research Findings

In their study, researchers compared two variants of Alzheimer’s model mice at 9 months of age with wild-type mice. Key findings include:

The study highlighted that amyloid beta (Aβ) was present in the bones of Alzheimer’s model mice and suggested a direct linkage between these amyloids and nerve tissue. Notably, while older wild-type mice exhibited Aβ deposits, it appeared that the amyloids stabilized around fat cells in the bone marrow, indicating a protective relationship.

Senescent Cells and Bone Loss

Further examination revealed that fat cells in the bones of Alzheimer’s mice displayed significant markers of cellular senescence, including:

• p16 - a cyclin-dependent kinase inhibitor.
• p21 - a critical regulator of cell cycle progression.
• SA-β-gal - a marker used for senescence detection.
• γH2AX - indicative of DNA damage response.

When these senescent fat cells were transplanted into younger wild-type mice, the resultant bone loss confirmed that the SASP from these senescent cells was responsible for accelerating osteoporosis.

A Connection Between SASP Factors and Amyloid Aggregation

Researchers identified that a crucial factor in bone loss is SAP/PTX2, which is primarily found in senescent fat cells. Additional studies demonstrated that administering treatments like dasatinib and quercetin or ruxolitinib, which inhibit the SASP, helped reduce SAP levels to be comparable to wild-type mice. Notably, SAP directly influenced amyloid aggregation, marking a significant discovery.

“The discovery of a SASP factor that causes amyloid aggregation opens new potential therapeutic pathways to address Alzheimer’s-related bone loss.” – Lead Researcher

Treatment Implications

Further investigations involving the compound CPHPC, which targets SAP, showcased promise against both Aβ deposition and bone loss in Alzheimer's model mice. Notably, a reduction in osteoclast prevalence was observed, suggesting a reduction in bone degradation.

While this association provides a fresh avenue for intervention, more research is needed to explore the effectiveness of senolytics and similar compounds in human treatments for amyloid-related osteoporosis.

Conclusion

The findings significantly highlight a previously unrecognized link between bone health and neurodegenerative diseases like Alzheimer’s. Understanding and targeting the SASP factors may deliver new strategies for therapeutic development, aiming to mitigate the impacts of both osteoporosis and Alzheimer’s disease.

Literature Cited

• [1] Gertz, M. A., et al. (2005). Definition of organ involvement... _American Journal of Hematology_.
• [2] Gertz, M. A., & Dispenzieri, A. (2020). Systemic amyloidosis recognition... _Jama_.
• [3] Hipp, M. S., et al. (2019). The proteostasis network... _Nature Reviews Molecular Cell Biology_.
• [4] Tan, Z. S., et al. (2005). Bone mineral density and Alzheimer disease... _Archives of Neurology_.
• [5] Dengler-Crish, C. M., et al. (2018). Evidence of Wnt/β-catenin alterations... _Neurobiology of Aging_.
• [6] Mihara, S., et al. (1994). Intervertebral disc amyloidosis... _Histopathology_.

Support Independent Journalism: We are a non-profit foundation committed to delivering free educational content. Your contributions help sustain our unbiased reporting. Every little bit counts!